David Ej Jones, Ulrich Beuers, Alan Bonder, Marco Carbone, Emma Culver, Jessica Dyson, Robert G Gish, Bettina E Hansen, Gideon Hirschfield, Rebecca Jones, Kris Kowdley, Andreas E Kremer, Keith Lindor, Marlyn Mayo, George Mells, James Neuberger, Martin Prince, Mark Swain, Atsushi Tanaka, Douglas Thorburn, Michael Trauner, Palak Trivedi, Martin Weltman, Andrew Yeoman, Cynthia Levy
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of Ursodeoxycholic Acid (UDCA). Up to 40% of patients do not, however, respond adequately to UDCA and therefore still remain at risk of disease progression to cirrhosis. The introduction of Obeticholic acid (OCA) as second-line therapy for patients failing UDCA has improved outcomes for PBC patients. There remains, however, a need for better treatments for higher risk patients...
March 22, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases